LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Fermé

SecteurSoins de santé

8.28 -0.24

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.27

Max

8.46

Chiffres clés

By Trading Economics

Revenu

5.1M

5.1M

Ventes

18M

163M

Marge bénéficiaire

3.113

Employés

580

EBITDA

-84M

-62M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+110.59% upside

Dividendes

By Dow Jones

Prochains Résultats

3 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-88M

1.7B

Ouverture précédente

8.52

Clôture précédente

8.28

Sentiment de l'Actualité

By Acuity

32%

68%

94 / 371 Classement par Healthcare

BioCryst Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 sept. 2025, 23:07 UTC

Acquisitions, Fusions, Rachats

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2 sept. 2025, 22:10 UTC

Principaux Mouvements du Marché

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2 sept. 2025, 21:47 UTC

Résultats

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2 sept. 2025, 16:52 UTC

Principaux Mouvements du Marché

CleanCore Solutions Shares Drop After $175 Million Private Investment

2 sept. 2025, 22:47 UTC

Market Talk

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2 sept. 2025, 21:40 UTC

Acquisitions, Fusions, Rachats

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2 sept. 2025, 21:07 UTC

Résultats

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2 sept. 2025, 21:07 UTC

Résultats

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2 sept. 2025, 21:05 UTC

Résultats

Couche-Tard 1Q Rev $17.35B >ATD.T

2 sept. 2025, 21:05 UTC

Résultats

Couche-Tard 1Q Adj EPS 78c >ATD.T

2 sept. 2025, 21:05 UTC

Résultats

Couche-Tard 1Q EPS 82c >ATD.T

2 sept. 2025, 21:05 UTC

Résultats

Couche-Tard 1Q Net $782.5M >ATD.T

2 sept. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

2 sept. 2025, 20:53 UTC

Market Talk
Acquisitions, Fusions, Rachats

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2 sept. 2025, 20:51 UTC

Acquisitions, Fusions, Rachats

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 sept. 2025, 20:27 UTC

Résultats

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2 sept. 2025, 20:24 UTC

Acquisitions, Fusions, Rachats

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2 sept. 2025, 20:18 UTC

Acquisitions, Fusions, Rachats

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2 sept. 2025, 20:17 UTC

Acquisitions, Fusions, Rachats

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2 sept. 2025, 20:16 UTC

Acquisitions, Fusions, Rachats

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2 sept. 2025, 20:16 UTC

Acquisitions, Fusions, Rachats

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2 sept. 2025, 20:15 UTC

Acquisitions, Fusions, Rachats

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2 sept. 2025, 19:55 UTC

Résultats

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2 sept. 2025, 19:50 UTC

Acquisitions, Fusions, Rachats

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2 sept. 2025, 19:09 UTC

Market Talk

Oil Futures Gain on Geopolitical Premium -- Market Talk

2 sept. 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2 sept. 2025, 18:12 UTC

Market Talk

Gold Pushes To New Record -- Market Talk

2 sept. 2025, 17:04 UTC

Market Talk

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2 sept. 2025, 16:57 UTC

Acquisitions, Fusions, Rachats

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Comparaison

Variation de prix

BioCryst Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

110.59% hausse

Prévisions sur 12 Mois

Moyen 17.5 USD  110.59%

Haut 30 USD

Bas 12 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

94 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.